article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,

article thumbnail

U.S. Funding Focuses on Marijuana’s Harms, Not Benefits

CannaMD

research funders, the National Institute on Drug Abuse (NIDA) , spent over $1 billion between 2000 and 2008, with a heavily slanted focus on cannabis abuse and misuse, as well as the negative effects of cannabis. Drug Enforcement Agency (DEA) announced that it will evaluate 37 additional grower applications. One of the largest U.S.

DEA 105
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 32: United States DEA.